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ABSTRACT 
The Royal College of Pathologists (RCPath) and College of American Pathologists 
recommend that at least 12 lymph nodes should be harvested for adequate staging 
of colorectal carcinoma.  Just one nodal tumour deposit upstages the malignancy 
from pN0 to pN1.  This is critically important as node-positive patients (pN1) are 
considered for adjuvant chemotherapy whereas node negative patients (pN0) may 
not be.  It is not always easy to harvest the required number, especially in patients 
with rectal carcinoma who may have received neoadjuvant therapy – an increasingly 
common treatment.  The use of neoadjuvant therapy is known to further decrease 
the number and size of identifiable lymph nodes within specimens, meaning that the 
lymph node harvest often fails to reach RCPath guidelines. 
  
Lymph node revealing solutions consisting of either single chemicals such as alcohol 
or acetone, or compounds have been investigated to help improve the lymph node 
harvest in difficult specimens, e.g. those received following neoadjuvant 
therapy.  Published research evidence reviewed here suggests that lymph node 
revealing solutions significantly improve lymph node harvesting, and that glacial 
acetic acid, ethanol, water and formalin (GEWF) is advantageous in comparison to 
other revealing solutions in that it is safe, cheap, easy to use and relatively quick.  
However, the quantity of good evidence is limited and the clinical implications of 
improving lymph node harvesting require further research. 
 
 
 
 
 
 
 
MAIN TEXT 
 
INTRODUCTION  
Colorectal carcinoma (CRC) is the fourth most common cancer in the UK.[1]  In 2010 
alone there were 40,695 new diagnoses and 16,013 deaths from the disease.[2]  
High quality histopathological assessment, including harvesting of an adequate 
number of lymph nodes is required in order to accurately stage the patient and help 
deliver the most appropriate treatment post-surgery.  The presence of metastases 
within lymph nodes is inextricably linked to the prognosis of the patient.[3] 
 
Current recommendations are that at least 12 lymph nodes should be retrieved for 
adequate staging of CRC,[4-5] with all mesentery within the tumour vicinity 
searched. Just one nodal tumour deposit upstages the malignancy from pN0 to 
pN1.[4]  This is important as node-positive patients (pN1) are considered for 
adjuvant chemotherapy whereas node negative patients (pN0) may not be.[6]   
 
The requirement for at least 12 lymph nodes is based on evidence demonstrating the 
prognostic significance of lymph node harvesting.[7-8]  Some literature suggests that 
more lymph nodes should be harvested for adequate staging,[7] but 12 is the current 
consensus.[4-5]  At our hospital, specimens are re-sampled when less than 12 
lymph nodes are harvested at the first attempt.  
 
Lymph node harvesting is traditionally performed by a manual technique of vision 
and palpation.  In the majority of cases harvesting a minimum of 12 lymph nodes 
should be achievable but this may become more difficult in the rectum, especially in 
patients who have received neoadjuvant chemotherapy as the size of lymph nodes 
may be reduced, making identification more challenging.[9]   Use of neoadjuvant 
therapy is not the sole cause of an inadequate lymph node harvest.  Other limiting 
factors are known to be fixation time,[3,10] experience of the surgeon and failure by 
the dissector to appropriately examine all nodes within a specimen, either due to lack 
of experience or poor technique.[11-12] 
 
In response to this, a number of studies have been carried out to address the issue 
of lymph node harvesting, using a variety of methods.  These have included 
extending the fixation time,[3,13-14] injecting dyes to accurately map lymph node 
chains,[15-16] transilluminating the mesentery to identify small nodes,[17-22] 
submitting residual mesenteric tissue in its entirety,[23] and using a variety of 
different lymph node revealing solutions.[3,17-44]  In many studies these techniques 
have been combined.[17-24,27-28,31-34]  
 
This review is based on a search of medical and scientific databases to identify all 
available literature written in English, and published within the last thirty years.  The 
review focuses on the use of chemical lymph node revealing solutions in relation to 
CRC specimens only.  Studies related to other carcinoma types are excluded from 
this review, as are those which use other adjunct techniques such as lymph node 
mapping.  The studies within this review are mainly of cohort and case control 
design,[3,17-37,39-44] although there is also one randomised controlled trial.[38]    
 
HISTORY OF LYMPH NODE REVEALING SOLUTIONS  
Since the first fat clearance technique using dye injection and lymph node mapping 
with alcohol clearance was described by Gilchrist et al in 1938,[24] authors have 
studied a variety of lymph node revealing solutions.[17-43]  A number of early 
studies investigated the use of alcohols, acetone and xylene,[17-19,21-22,26,28,30-
33] but since 1997 when the first study was published,[41] there has been a greater 
focus on the use of glacial acetic acid, ethanol, water and formalin (GEWF) (Table 
1).[35-42]  
 
REVIEW OF THE LITERATURE 
Number of lymph nodes retrieved 
The most commonly described benefit of using lymph node revealing solutions is the 
pure increase in the numbers of lymph nodes harvested, many of which are of a 
smaller size than might be identified by manual dissection.  Studies have shown a 
variable increase in harvested lymph nodes.  In one study, a mean harvest of 76.4 
and 73.7 lymph nodes was seen after application of alcohol in colonic and rectal 
resections respectively.[19]  In the same study, a secondary manual dissection 
identified a mean of 18.1 and 21.2 lymph nodes respectively; but the authors did not 
clarify whether both sets of dissections were performed by the same individuals.[19]  
If manual dissections had been carried out by less experienced individuals then it is 
possible that this may have also affected the numbers of nodes harvested.   
 
Metastatic incidence and upstaging 
Metastatic incidence refers to the proportion of lymph nodes which contain tumour 
deposits.  A decrease in metastatic incidence after the use of lymph node revealing 
solutions has been reported.[17-18,22,25,27,31,38,40-42]  Saleki et al attributed 
significance to this finding, stating it to be due to the overall greater number of lymph 
nodes harvested after secondary dissection.[40]   In contrast, five studies showed an 
increase in metastatic incidence,[29,32,36-37,39] but not always with 
significance.[37,39]   
 
Upstaging refers to an upwards change in pathological staging, which may then alter 
patient treatment if there is a shift from node negative (pN0) to node positive (pN1 or 
pN2).  This is because node-positive patients receive chemotherapy, while node-
negative patients may not.[45] 
 
Nine studies reported upstaging after the use of lymph node revealing 
solutions,[17,23,25,27,31-32,40-42] ranging from 2.4% to 33%  (Table 2).[31,41]  Six 
of these claimed the finding to be significant, in that upstaging from Dukes’ B to 
Dukes’ C was reported, prompting adjuvant therapy.[17,25,27,32,40-41]  However, 
this may not have been a correct assumption because most of these studies had 
questionable underlying primary manual dissection practice with fewer than the 
recommended minimum of 12 lymph nodes found on average (range 2.94 – 
7.3).[17,25,32,40-41]  These studies were therefore more likely to identify upstaging 
once a lymph node revealing solution had been applied.  It is likely that upstaging 
would have been insignificant, or not present at all, had there been optimal primary 
manual dissection.  In one study by Koren et al, not only was there upstaging in 10 
cases, but a further eight cases also had the staging changed from Nx to N0, 
suggesting an underlying deficit in primary manual dissection technique.[41]  The 
case upstaged by Brown et al was a soft tissue metastasis which the authors 
suggested may have been artefactual.[27]  The evidence in the literature is therefore 
questionable.   
 
Does lymph node size matter? 
Multiple studies have demonstrated smaller sized lymph nodes after lymph node 
revealing solutions are used (Table 4).[3,18-19,22,25,36,39-40,42,44]  Some of the 
more recent studies using GEWF have assessed and attributed statistical 
significance to this.[36,39-40,42]  Brown et al found that 83% of additional lymph 
nodes were ≤ 2mm in size.[27]  Where GEWF is used this may be due to the white 
colour of lymph nodes which facilitates detection.[39]  There is ongoing debate 
regarding the clinical significance of CRC metastases in small lymph nodes.  Dhar et 
al concluded that metastatic lymph node size is a strong prognostic variable in CRC, 
using two sample log rank testing to demonstrate that the prognostic impact 
decreased when lymph nodes were more than 10mm in diameter.[55]  Dhar et al did 
concede that their findings needed to be confirmed with a larger study before clinical 
application.[55]  In another recent study Märkl et al concluded that “minute lymph 
nodes [<1mm] have virtually no role in correct histopathological lymph node 
staging”.[56]  They did however agree that the detection of relatively small lymph 
nodes (1-5mm) was an important factor for exact lymph node staging and was 
prognostically relevant, with an association between a high number of harvested 
lymph nodes and a favourable outcome in colon carcinoma.[56]   
 
It is important to consider whether finding a greater number of smaller lymph nodes 
has the potential to change patient management.  If the only significant finding is a 
greater number of smaller tumour-free lymph nodes, then the patient will remain 
node negative and there will be no change in treatment.  There will be no benefit to 
the patient but there will be a cost to the laboratory, both in terms of increased 
turnaround times and finances.   
 
If metastases are prevalent in larger lymph nodes (i.e. >5mm), then they should be 
identified by manual dissection, providing the dissector is adequately experienced.  If 
this is the case then one might argue that the use of lymph node revealing solutions 
is not necessary.  It may be that education is as important a tool as is the use of 
adjunct chemicals, but currently there remains a lack of evidence to prove or 
disprove this.   
 
CHALLENGES IN STUDY DESIGN 
Quality of evidence 
The greatest challenge in assessing the true value of lymph node revealing solutions 
in CRC surrounds the quality of the existing evidence.  The majority of existing 
studies are open to at least one type of bias which may invalidate the conclusions.  
Different types of bias which may have affected the existing studies are summarised 
in Table 3.  
 
Underlying primary dissection practice 
Many of the studies did not achieve the recommended targets during primary manual 
dissection,[17,22,25,29,32,35-36,38-42] with the mean number of lymph nodes 
harvested ranging from 2.7,[22] to 21.2.[19]  Kelder et al only found a mean of 5.0 
lymph nodes by primary manual dissection in 117 colonic specimens, even though 
their study was relatively recent.[39]  The highest number of lymph nodes found in 
any specimen in their study was only 17,[39] which was lower than the average 
number found by primary manual dissection in a number of other 
studies.[19,23,27,30,37]  In the study by Schmitz-Moorman et al, routine primary 
dissection yielded a mean nodal count of 2.7, and failed to identify any nodes in six 
out of the 75 cases.[22]  This issue is supported by a number of studies where the 
importance of enthusiasm and skill of both pathologist and surgeon is noted because 
it directly effects the quality of the specimen and subsequent nodal 
harvest.[18,35,42]  Gregurek et al found that educating pathologists in appropriate 
primary manual dissection practice gave more powerful results than the use of lymph 
node revealing solutions,[37] however there was potential bias in their study (Table 
3).  Additionally, failing to consider the experience of dissectors may also introduce 
sampling bias, perhaps via the involvement of inexperienced dissectors who might 
miss smaller lymph nodes in comparison to dissectors who are highly experienced in 
manual dissection.  It was often unclear in the case control studies who performed 
the secondary dissection.[17-24,26-29,31-43]  The exceptions to this were the 
studies by Jass et al and Vogel et al, where secondary dissection was performed by 
the first author,[30] or one of three pathologists not aware of the outcome of the 
primary dissection respectively.[25]  Only one of the studies included true 
randomisation of specimens into study groups.[38]  Gregurek et al claimed that 
cases were alternately enrolled into study and control groups; however, pathologists 
were given the opportunity to change this, which weakened their study design.[37]        
 
Blinding 
Studies involving GEWF will always have an immediate detection bias, caused by an 
inability to use blinding.  Iversen et al described GEWF as having “its own 
characteristic macroscopic appearance, which is impossible to hide”.[38]  This could 
then either consciously or unconsciously give dissectors the ability to alter their 
practice which could skew any potentially significant findings.  Newell et al admit to 
this limitation, commenting that “those pathologists using the standard technique 
would likely examine pericolic fat more thoroughly”.[36] 
 
Time and cost 
The most rapid treatments took six hours to complete and all used GEWF.[40-42]  In 
contrast, the longest treatment using a combination of alcohol and xylene took a 
minimum of three weeks.[32]  Unsurprisingly, many of the more lengthy treatments 
have been associated with multistep studies, where more than one chemical has 
been used in the lymph node revealing solution.[27-28,32]  Many studies taking a 
day or less of additional time to harvest lymph nodes used GEWF.[35-38,40-42]  
With the need to modernise National Health Service (NHS) histopathology 
departments,[46-49] it is unsurprising that focus appears to be shifting towards 
GEWF, which acts as a fixative whilst also clearing fat in a shorter period of time 
than other lymph node revealing solutions.  In the 21st century focusing on lengthy 
techniques cannot be justified.[46-49]  Even if lengthy multistep techniques are 
deemed to provide significant findings, it would be inappropriate to substantially 
delay reporting. In order to maintain and improve turnaround times, a quicker and 
more effective method of fat clearance is required if it is to be used routinely.  As well 
as adding a diagnostic delay, older lymph node revealing solutions are also said to 
be expensive.[42]      
 
Toxicity 
 
Many older studies used noxious substances, most notably the aromatic 
hydrocarbon xylene.[17-22,28,30-34]  Xylene was once ubiquitous in histopathology 
laboratories as a clearing agent used routinely in processing and staining.  
Laboratories are now seeking to eliminate the use of xylene in processing,[50-52] 
due to its known carcinogenic potential.[50]  This has been facilitated by the 
introduction of xylene-free processing technology.[53-54]  As a result of this, only 
one study in the last ten years has included xylene.[27]  In contrast, there have been 
a number of recent studies assessing the use of GEWF, which is seen as a better 
lymph node revealing solution than its predecessors because it is safe, cheap, easy 
to prepare and handle,[3,35-36,38-41,43-44] odourless, can be used with standard 
ventilation, and has no adverse effect on routine special stains or 
immunohistochemistry.[36]  
 
CONCLUSIONS  
As yet, there is no clear evidence to indicate whether one lymph node revealing 
solution is better than another from the current literature; however the use of 
carcinogenic chemicals is inappropriate in terms of health and safety.[17-22,25-
28,30-34] Lengthy lymph node revealing techniques which add significant reporting 
delays,[19,27-28,32] are inappropriate in a modern NHS.[46-49]  A number of 
studies have claimed that GEWF is a safe and efficient lymph node revealing 
solution,[19,36-42] which is quick, cheap, easy to prepare and handle.[18,39,41]  In 
their prospective case control study Üstün et al stated that historical fat clearance 
techniques were difficult to handle and expensive whilst GEWF was easier to use 
with better results.[42]  GEWF could be further investigated with appropriately 
designed studies, adopting randomisation of cases and minimisation of any potential 
bias which has been an issue in the existing literature.  It is difficult to determine 
whether the use of GEWF or any other lymph node revealing solution leads to 
upstaging from node negative to node positive; bias in existing studies limits their 
conclusions.  Until evidence can show that the use of lymph node revealing solutions 
significantly affects patient management, their routine use cannot be recommended 
as no benefit to the patient has yet been proven.  The next steps should be to design 
appropriate studies in order to look for statistically significant differences in lymph 
node harvest associated with the use of these solutions.  This would help to test the 
hypothesis that the use of lymph node revealing solutions contributes to patient 
management and would ensure that the most appropriate evidence-based treatment 
options are available to patients.      
 
TAKE HOME MESSAGES 
 The use of lymph node revealing solutions leads to a significant increase in 
the number of harvested lymph nodes in CRC resection specimens. 
 
 The use of lymph node revealing solutions leads to detection of significantly 
smaller lymph nodes and may lead to upstaging, which can change patient 
management by prompting adjuvant therapy.  It has yet to be shown whether 
these findings have any clinical significance and therefore whether they can 
enhance patient management. 
 
 GEWF is a safe and efficient lymph node revealing solution and its potential 
utility should be investigated further.  Other older lymph node revealing 
solutions such as xylene have cost implications - in terms of finance, 
turnaround times and health effects; therefore studies of their use are no 
longer relevant to modern practice. 
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TABLES 
Table 1.  Number of harvested lymph nodes. 
 
Lymph node revealing 
solution 
 
 
Manual dissection 
 
Fat clearance 
 
Statistically 
significant 
difference? 
 No. 
cases 
Mean no. 
lymph 
nodes 
No. 
cases 
Mean no. 
lymph nodes / 
(+) additional 
nodes) 
 
Acetone*[25] 34 
80 
15.4 
6.9 
34 
80 
+5.7 
+4.4 
- 
Acetone/IPA/oil[26] - - 864 27.0 - 
Acetone/xylene[22] 75 2.7 75 +7.5 - 
Acetone/alcohol/ xylene[18] 22 4.7 10 30.9 Yes 
(p<0.0001) 
Acetone/alcohol/xylene[27] 15 20.9 15 +68.6 - 
Acetone/alcohol/ xylene[28] - - 311 74.3 - 
Alcohol[23] 48 19.4 48 +23.6 No (p=0.177) 
Alcohol**[29] 82 9.6 
5.2 
155 27.6 
20.4  
Yes (p<0.001) 
Yes (p<0.001) 
Alcohol[33] - - 27 34 - 
Alcohol***[19] 37 18.1/21.2 140/182 76.4/73.7 - 
Alcohol/xylene[31] 41 21 43 -9/-4 - 
Alcohol/xylene[30] 10 18.7 10 -2.3 No (p=0.57) 
Alcohol/xylene[32] 103 6.2 103 +12.4 - 
Alcohol/xylene****[21] 221 
50 
10.5 
13.1  
51 23.1 Yes (p<0.001) 
Alcohol/xylene[17] 41 7.3 41 +47.6 - 
Alcohol/xylene[20] - - 48 50.2 - 
GEWF[37] 40 18.30 45 19.96 No (p=0.53) 
GEWF*****[42] 30 
12 
5.1 
6.25+1.6 
30 
12 
+1.73 
+1.2 
Yes (p<0.01) 
Yes (p<0.01) 
GEWF[36] 32 6.8 35 10.2 Yes (p=0.002) 
GEWF[41] 30 2.94 30 +8.6 - 
GEWF[40] 35 6.26 35 +13.0 - 
GEWF***[38] 59 10 
9  
61 17 
16 
Yes (p<0.001) 
GEWF[39] 117 5.0 125 13.0 Yes (p<0.001) 
GEWF[35] 34 5.9 59 14.7 Yes (p=0.05) 
GEWF[3] 423 11.4 423 +6.0 - 
GEWF******[43] 76 - 62 - - 
GEWF[44] 8 7.6 8 +4.7 Yes (p<0.5) 
*two study groups 
**non-neoadjuvant/neoadjuvant 
***colonic / rectal 
****multiple sites with lymph node clearance performed at the main site only 
*****two study groups, multiple dissections and multiple sites of tumour 
******comparison of cases from different years; also includes assessment of improved surgical 
practice  
 
 
 
 
 
 
Table 2.  Incidence of upstaging. 
 
 
Lymph node revealing 
solution 
 
 
Findings 
 
Acetone[25]
 
2/34 (5.9%) upstaged from pN1 to pN2
†
 
2/80 (2.5%) upstaged
††
: 
1 upstaged from pN0 to pN1 
1 upstaged from pN1 to pN2 
Alcohol and xylene[17] 3/41 (7.3%) cases upstaged from Dukes’ B to Dukes’ C 
GEWF[41] 10/30 (33%) upstaged
†††
: 
4 upstaged from Nx – N1 
4 upstaged from N0 – N1 
2 upstaged from N1 – N2  
GEWF[42] 4/30 (13.0%) upstaged – no colorectal cancer cases upstaged
††††
 
Alcohol and xylene[32] 5/58 (8.6%) upstaged (Dukes’ B to Dukes’ C) 
GEWF[40] 3/35 (8.6%) upstaged from Dukes’ B to Dukes’ C 
Acetone, alcohol and 
xylene[27] 
4/15 (26.7%) upstaged: 
1 upstaged from pN0 – pN1 
3 upstaged from pN1 – pN2 
Alcohol and xylene[31] Stage changed in 2/84 (2.4%) of cases 
Alcohol[23] 2/10 (20.0%) upstaged from pN1 – pN2 
†
Control group 
††
Study group 
†††
Stage also changed from Nx – N0 in 8 cases 
††††
Upstaged 1 breast carcinoma and 3 bladder carcinoma cases 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 3.  Types of bias within the literature.   
Anatomical variation in numbers of lymph nodes within the colorectum[17,19-20,23,25-
26,28,32,34,36-38,40-42] 
Suboptimal underlying manual dissection practice[3,17,22,25,29,32,35-36,38-42] 
Inappropriate or unclear sample size[17,20,27,29-30,33,37,44] 
Unclear or unbalanced study groups[17-19,22-23,25,29,40,42] 
No sample size calculation[19,22,25,27-28,30-31,33,37,39-40,44] 
Exclusion criteria unclear or absent[17,36,38] 
No randomisation used / strategy unclear[22-23,27,31-32,35] 
Inability to use blinding[22,35-36,38] 
No statistics used or described[3,17,22,25,31,33]  
 
 
Statistics used but methods not defined or discussed[40] 
Intervention and comparison compared during different study periods[29,37] 
Unclear or varying fixation time[29,35-37] 
Unclear length of time in lymph node revealing solution[39] 
Lengthy / unclear timescale of study[22,27,29] 
Staff allowed to choose which technique to use[37] 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 4.  The effect of lymph node revealing solutions on the size of lymph nodes. 
 
Lymph node 
revealing 
solution 
 
Control group 
 
Study group 
 
 
Statistically 
significant 
difference? 
Acetone[25] Average diameter 2.7mm 
 
Average diameter 2.0mm 
 
- 
Acetone, IPA 
and oil[26] 
- - - 
Acetone and 
xylene[22] 
9.7% nodes ≤2mm,  
10% metastatic nodes ≤2mm 
83.6% nodes ≤2mm 
0.6% metastatic nodes ≤2mm 
- 
Acetone, 
alcohol and 
xylene[18] 
4.8% nodes <5mm  
100% metastatic nodes >5mm 
89% nodes <5mm 
40% metastatic nodes <5mm 
- 
Acetone, 
alcohol and 
xylene[27] 
- 50% nodes <1mm 
82% nodes <2mm 
83% metastatic nodes <3mm 
In both groups, 75% metastatic 
nodes <2mm 
- 
Acetone, 
alcohol and 
xylene[28] 
- - - 
Alcohol[23] - 88.6% nodes ≤2mm 
78.6% metastatic nodes ≤2mm 
- 
Alcohol[29] - - - 
Alcohol[33] - 75.5% metastatic nodes <5mm 
24.5% metastatic nodes >5mm 
- 
Alcohol[19] 49.5% nodes <4mm  
14.8% metastatic nodes <4mm  
77.9% nodes <4mm 
32.6% metastatic nodes <4mm 
- 
Alcohol and 
xylene[31] 
- - - 
Alcohol and 
xylene[32] 
- - - 
Alcohol and 
xylene[21] 
- - - 
Alcohol and 
xylene[17] 
- 77% of metastatic nodes ≤5mm 
In 7 cases metastases only 
found in nodes ≤5mm 
- 
Alcohol and 
xylene[20] 
- 94% nodes ≤5mm 
6% nodes >6mm 
71.8% metastatic nodes ≤5mm 
- 
GEWF[42] Mean diameter 6.8mm (±4.13) Mean diameter 4.2mm (±3.46) Yes (p<0.01) 
GEWF[36] Average diameter of metastatic 
nodes 7mm (±4mm)  
41% nodes ≤5mm 
Average diameter of metastatic 
nodes 5mm (±2mm) 
60% nodes ≤5mm 
Yes (0.046) 
GEWF[41] - Diameter 0.5 -7.0mm - 
GEWF[40] Mean diameter 0.429mm 
(minimum 0.1mm) 
All nodes >0.9mm identified by 
standard technique   
Mean diameter metastatic 
nodes 0.568mm  
26% nodes <5mm identified by 
standard practice 
55.3% metastatic nodes ≤5mm  
Mean diameter 0.268mm (0.2-
0.9mm) 
Mean diameter metastatic 
nodes 0.35mm 
Yes 
(p<0.000001) 
GEWF[39] Median diameter non-
metastatic nodes 6mm 
Median diameter metastatic 
Median diameter non-
metastatic nodes 4mm 
Median diameter metastatic 
Yes 
(p<0.001) 
 
nodes 9mm  nodes 6mm  Yes 
(p<0.001) 
GEWF*[35] - 86% nodes (246/286) <3mm 
11.5% nodes (33/286) 3-6mm 
1.4% nodes (4/286) >6mm 
6 metastatic nodes <3mm (5 
from neoadjuvant therapy 
cases)  
- 
GEWF[3] Mean diameter 4.3mm Mean diameter 2.5mm - 
GEWF[44] Mean diameter 2.6mm (1-
15mm) 
Mean diameter 2.1mm (1– 
4mm) 
No (p>0.11) 
*only assessed 30.5% of cases in the study group 
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